Home

Download

Statistics

Landscape

Help

Contact

	Gene summary
	Datasets with differential expression of this gene
	Expression of this gene in the resistant group across all datasets and cell types
	Significant ligand-receptor pairs related to this gene (This gene does not contain this module)
	Known drug resistance mechanisms of this gene (This gene does not contain this module)
	MicroRNAs (miRNAs) regulating this gene
	Motifs and transcription factors (TFs) regulating this gene
	Acts as a transcription factor (This gene does not contain this module)
	Acts as a drug target< (This gene does not contain this module)

Gene: RGCC

Summary for RGCC

Gene information	Gene symbol	RGCC
	Ensembl ID	ENSG00000102760
	Entrez ID	28984
	Gene name	regulator of cell cycle
	Synonyms	bA157L14.2\|C13orf15\|RGC-32\|RGC32
	Gene type	protein_coding
	UniProtAcc	Q9H4X1

Top

Dataset with differentially expressed gene: RGCC

Differentially expression genes between the resistant and sensitive groups. A positive avg_log2FC represents significantly high expression in the resistant group, while a negative avg_log2FC represents significantly low expression in the resistant group.

Dataset	Source	Tissue	Cancer type level1	Cancer type level2	Drug type	Regimen	Timepoint	Cell type	avg_log2FC	p_val_adj
GSE140440	DU145 and PC cell lines	Cell line	Prostate cancer	Prostate cancer	Chemotherapy	docetaxel	NA	Malignant cells	4.54134	4.70e-13
GSE163836	FCIBC02 cell line	Cell line	Breast cancer	Inflammatory breast cancer	Chemotherapy	paclitaxel	NA	Malignant cells	-0.660237	0.00e+00
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	post	CD4+ T cells	-0.646596	0.00e+00
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	post	NK cells	0.73054	1.10e-39
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	Plasma cells	0.431872	2.56e-39
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	pre	B cells	-0.458063	3.66e-05
GSE164551	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Immunotherapy	CAR-T	NA	CD8+ T cells	-0.988258	4.96e-16
GSE164551	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Immunotherapy	CAR-T	NA	Mono/Macro	-1.16522	0.00e+00
PMID34715028	patients	Tumor tissue	Kidney cancer	Clear cell renal cell carcinoma (ccRCC)	Immunotherapy	nivolumab	post	CD4+ T cells	-2.09865	0.00e+00
PMID34715028	patients	Tumor tissue	Kidney cancer	Clear cell renal cell carcinoma (ccRCC)	Immunotherapy	nivolumab	post	CD8+ T cells	-1.98945	0.00e+00
GSE150930	patients	Peripheral blood mononuclear cells	Chronic lymphocytic leukemia	Mucosa-assisted lymphoid tissue (MALT) lymphoma	Immunotherapy	rituximab + cyclophosphamide + fludarabine	NA	Malignant cells	-0.445879	4.64e-21
GSE207422_Sin	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	sintilimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	CD8+ T cells	0.756477	2.29e-25
GSE207422_Sin	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	sintilimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	Mono/Macro	-0.542598	2.69e-15
GSE207422_Tor	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	toripalimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	CD8+ T cells	0.36546	3.42e-03
GSE207422_Tor	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	toripalimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	Plasma cells	0.549911	2.87e-03
GSE207422_Tor	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	toripalimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	CD4+ T cells	0.47129	1.18e-04
GSE189460	patients	Bone marrow aspirate	Multiple myeloma	Multiple myeloma (MM)	Targeted therapy	bortezomib + melphalan + prednisolone	pre	NK cells	-0.381851	1.89e-36
GSE189460	patients	Bone marrow aspirate	Multiple myeloma	Multiple myeloma (MM)	Targeted therapy	bortezomib + melphalan + prednisolone	pre	Mono/Macro	-0.611211	1.55e-39
GSE189460	patients	Bone marrow aspirate	Multiple myeloma	Multiple myeloma (MM)	Targeted therapy	bortezomib + melphalan + prednisolone	pre	CD8+ T cells	-0.51324	4.21e-33
GSE189460	patients	Bone marrow aspirate	Multiple myeloma	Multiple myeloma (MM)	Targeted therapy	bortezomib + melphalan + prednisolone	pre	Malignant cells	0.362166	0.00e+00
GSE161801_PI	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	carfilzomib + dexamethasone	pre	CD8+ T cells	0.309925	8.19e-19
GSE161801_PI	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	carfilzomib + dexamethasone	pre	Mono/Macro	0.308022	1.12e-14
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	post	Malignant cells	-1.64972	0.00e+00
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	post	CD8+ T cells	0.63169	0.00e+00
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	post	Erythrocytes	0.545628	0.00e+00
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	pre	Malignant cells	-0.512918	0.00e+00
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	pre	CD8+ T cells	0.774122	6.19e-17
GSE152469	patients	Peripheral blood mononuclear cells	Chronic lymphocytic leukemia	Chronic lymphocytic leukemia (CLL)	Targeted therapy	ibrutinib	NA	Malignant cells	0.404061	0.00e+00
GSE161801_IMiD	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	pomalidomide + dexamethasone OR lenalidomide + dexamethasone	post	Malignant cells	0.634558	0.00e+00
GSE161801_IMiD	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	pomalidomide + dexamethasone OR lenalidomide + dexamethasone	pre	cDCs	-0.378989	9.12e-03

Top

Expression of RGCC in the resistant group across all datasets and cell types

Red dots represent significantly high expression in the resistant group, while blue dots represent significantly low expression in the resistant group. White dots represent that there is no significant difference in the expression of this gene between the resistant and sensitive groups. Blank represents that this cell type is not present in this dataset. (If the image exists, the user can click on it to enlarge it in a new window.)

Top

Significant ligand-receptor pairs related to RGCC

This table shows the significant ligand-receptor pairs related to this gene across all datasets, timepoints and conditions. (Complete files can be downloaded from the download section.)

Top

Known drug resistance mechanisms of this gene

This table shows the known drug resistance mechanisms of this gene. Clicking on this gene will link to another database that displays more drug resistance-related information.

Top

MicroRNAs (miRNA) regulating RGCC

This table shows the miRNAs with a score of more than 80 regulating this gene. (Complete files can be downloaded from the download section.)

Gene symbol	miRNA	Score	GeneBank accession
RGCC	hsa-miR-5011-5p	94.7675	NM_014059
RGCC	hsa-miR-656-3p	94.6244	NM_014059
RGCC	hsa-miR-548e-5p	92.4619	NM_014059
RGCC	hsa-miR-4307	92.3102	NM_014059
RGCC	hsa-miR-7856-5p	91.7075	NM_014059
RGCC	hsa-miR-520d-5p	91.388	NM_014059
RGCC	hsa-miR-524-5p	91.388	NM_014059
RGCC	hsa-miR-4287	91.1844	NM_014059
RGCC	hsa-miR-4685-3p	91.1844	NM_014059
RGCC	hsa-miR-1277-5p	91.1747	NM_014059
RGCC	hsa-miR-6867-3p	86.6886	NM_014059
RGCC	hsa-miR-4446-3p	82.165	NM_014059

Page: 1

Top

Motifs and transcription factors (TFs) regulating RGCC

This table shows the Motifs and transcription factors (TFs) regulating this gene. (Complete files can be downloaded from the download section.)

Gene symbol	motif	TF_highConf
RGCC	hocomoco__TYY2_HUMAN.H11MO.0.D	YY2 (directAnnotation).
RGCC	transfac_pro__M02015	FOXA3 (directAnnotation).
RGCC	transfac_pro__M05905	ZNF649 (directAnnotation).
RGCC	metacluster_141.6	MZF1; TAF1; YY1; YY1; YY1; YY1; YY1; YY1; YY1; YY1; YY1; YY1; YY1; YY1; YY2; YY2; ZFP42; ZFP42; ZFP42; ZFP42; ZFP42; ZFP42; ZNF597 (directAnnotation). TAF1; TAF1L (inferredBy_Orthology).
RGCC	kznf__ZNF613_Imbeault2017_RP_RCADE	ZNF613 (directAnnotation).
RGCC	transfac_pro__M05607	MYBL1 (directAnnotation).
RGCC	metacluster_168.3	NR4A1 (directAnnotation).
RGCC	metacluster_130.15	ARID5B; ARID5B; BPTF (directAnnotation).
RGCC	tfdimers__MD00156	CRX (directAnnotation).
RGCC	taipale_tf_pairs__FOXJ2_HOXB13_TTTWATNRNMAACA_CAP_repr	FOXJ2; HOXB13 (directAnnotation).
RGCC	hdpi__TRMT1	TRMT1 (directAnnotation).
RGCC	swissregulon__mm__Nkx2-3	NKX2-3 (inferredBy_Orthology).
RGCC	cisbp__M02686	NKX2-5 (inferredBy_Orthology).
RGCC	taipale_tf_pairs__ELK1_PAX5_RSCGGAACYACGCWYSANTG_CAP_repr	ELK1; PAX5 (directAnnotation).
RGCC	taipale_tf_pairs__GCM1_ETV4_RTGCGGGCGGAAGTR_CAP	ETV4; GCM1 (directAnnotation).
RGCC	transfac_pro__M07399	NKX6-1 (directAnnotation).
RGCC	metacluster_119.2	CCNT2; GATA1; GATA1; GATA1; GATA1; GATA2; GATA2; GATA2; NCOA1; TAL1; TAL1; TAL1; TAL1; ZNF823 (directAnnotation). GATA1; TAL1; TAL1; TAL1; TAL1 (inferredBy_Orthology).
RGCC	metacluster_27.9	ZSCAN31 (directAnnotation).
RGCC	metacluster_20.12	LHX8; LHX8 (directAnnotation).
RGCC	transfac_pro__M00727	NR5A1 (directAnnotation).
RGCC	taipale_tf_pairs__PBX4_HOXA10_NTCGTAAATCA_CAP_repr	HOXA10; PBX4 (directAnnotation).
RGCC	hdpi__ZBTB25	ZBTB25 (directAnnotation).
RGCC	transfac_public__M00095	CUX1 (directAnnotation).
RGCC	metacluster_143.1	ZSCAN31 (directAnnotation).
RGCC	tfdimers__MD00210	CDX2; HMBOX1 (directAnnotation).
RGCC	metacluster_194.1	BARHL1; BARHL2; BARHL2; BARHL2; ZNF354A; ZNF354A (directAnnotation). BARHL1 (inferredBy_Orthology).
RGCC	metacluster_25.2	LHX6; LHX6; LHX8 (directAnnotation).
RGCC	metacluster_150.8	PAX4; PAX4 (directAnnotation).
RGCC	cisbp__M00359	PAX3 (directAnnotation).
RGCC	dbtfbs__ZNF660_HEK293_ENCSR283DOU_merged_N1	ZNF660 (directAnnotation).
RGCC	tfdimers__MD00152	HOXA13; NKX6-2 (directAnnotation).
RGCC	jaspar__MA0707.2	MNX1 (directAnnotation).
RGCC	metacluster_20.4	DLX1; DLX1; DLX1; DLX2; DLX2; DLX2; DLX2; DLX3; DLX3; DLX3; DLX3; DLX4; DLX4; DLX5; DLX5; DLX5; DLX5; DLX6; DLX6 (directAnnotation).
RGCC	tfdimers__MD00328	HNF1A; HNF1B; NFYA; NFYB; NFYC (directAnnotation).
RGCC	cisbp__M00282	PHOX2B (directAnnotation).
RGCC	transfac_pro__M06778	ZFP37 (directAnnotation).
RGCC	metacluster_184.31	DLX2 (directAnnotation).
RGCC	transfac_pro__M01344	CUX1 (directAnnotation).
RGCC	taipale_tf_pairs__HOXB2_RFX5_TAATKRNNNNGCAAC_CAP_repr	HOXB2; RFX5 (directAnnotation).
RGCC	metacluster_20.5	DLX1; DLX4; DLX4 (directAnnotation).
RGCC	jaspar__MA0642.2	EN2 (directAnnotation).
RGCC	taipale_cyt_meth__LBX2_CTCGTTAN_eDBD_meth	LBX2 (directAnnotation).
RGCC	metacluster_7.7	SP2 (directAnnotation). KLF16 (inferredBy_Orthology).
RGCC	metacluster_77.20	SOX1 (inferredBy_Orthology).
RGCC	metacluster_77.14	SOX7 (inferredBy_Orthology).
RGCC	taipale_tf_pairs__HOXB2_SOX15_NYMATTANNNNNNACAATR_CAP_repr	HOXB2; SOX15 (directAnnotation).
RGCC	metacluster_126.14	ZBTB12; ZBTB12 (directAnnotation).
RGCC	transfac_pro__M05403	ADNP2 (inferredBy_Orthology).
RGCC	taipale_tf_pairs__FOXO1_HOXA10_RWMAACAYCRTWAA_CAP_repr	FOXO1; HOXA10 (directAnnotation).
RGCC	metacluster_161.18	DLX6 (directAnnotation).

Page: 1 2 3 4

Top

Acts as a transcription factor

This table shows that this differential gene acts as a transcription factor.

Top

Acts as a drug target

This table shows that this differential gene acts as a drug target.

1	"Sun X, Zhang Y, Li H, Zhou Y, Shi S, Chen Z, He X, Zhang H, Li F, Yin J, Mou M, Wang Y, Qiu Y, Zhu F. DRESIS: the first comprehensive landscape of drug resistance information. Nucleic Acids Res. 2023 Jan 6;51(D1):D1263-D1275. doi: 10.1093/nar/gkac812. PMID: 36243960; PMCID: PMC9825618."
2	"Wishart DS, Feunang YD, Guo AC, Lo EJ, Marcu A, Grant JR, Sajed T, Johnson D, Li C, Sayeeda Z, Assempour N, Iynkkaran I, Liu Y, Maciejewski A, Gale N, Wilson A, Chin L, Cummings R, Le D, Pon A, Knox C, Wilson M. DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018 Jan 4;46(D1):D1074-D1082. doi: 10.1093/nar/gkx1037. PMID: 29126136; PMCID: PMC5753335."